Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

42.34 +2.16 (+5.36%)
Delayed Quote Updated: 2:58 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
News headline image
2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 ↗
The pharmaceutical leader looks poised to stop the bleeding. 
Via The Motley Fool
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026
As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has... 
Via PredictStreet
Topics Economy Lawsuit World Trade
News headline image
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026 ↗
Via MarketBeat
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Why Novo Nordisk Stock Dropped on Monday ↗
The cost of Wegovy is about to decrease significantly in a populous overseas market. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
The 2026 Horizon: Wall Street Bets on the 'Application Era' and the Nuclear Renaissance
As the final trading days of 2025 come to a close, Wall Street is pivoting its focus from the hardware-driven "AI Gold Rush" toward a 2026 outlook defined by practical utility, autonomous software, and... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance
As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of... 
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
Market Breather: Benchmarks Pause Record-Breaking Year as Volatility Signals Year-End Reset
As the final trading days of 2025 approach, the relentless momentum that propelled major U.S. indices to historic heights has entered a period of measured consolidation. After a year defined by the... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
This Beaten-Down Stock Just Jumped By 8%. Time to Buy? ↗
Is this the start of a sustained run for the Danish drugmaker? 
Via The Motley Fool
News headline image
Novo Nordisk Slashes Weight Loss Drug Price By Up To 50% In China: Report ↗
Prices of Wegovy’s two highest doses were reduced to 987.48 yuan ($141) and 1,284.36 yuan, according to a Bloomberg article on Monday, citing Yicai. 
Via Stocktwits
Topics Intellectual Property
News headline image
The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. ↗
Other drugmakers seem to be too far behind to disrupt this duopoly, at least for now. 
Via The Motley Fool
News headline image
3 Drug Stocks to Buy at a Discount ↗
The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Invest in Ozempic Maker Novo Nordisk in 2026? ↗
The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back. 
Via The Motley Fool
News headline image
Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026 ↗
Via MarketBeat
News headline image
This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling ↗
The FDA is expected to issue a decision on Vanda’s Tradipitant, a motion-sickness treatment aimed at preventing vomiting, on Dec. 30, 2025. 
Via Stocktwits
News headline image
Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree ↗
A key product portfolio is bringing in blockbuster revenue. 
Via The Motley Fool
News headline image
Betting on the 'Santa Squeeze': Unusual Options Activity Surges as 2025 Draws to a Close
As the sun sets on 2025, the U.S. stock market is not entering the quiet holiday lull typical of decades past. Instead, a massive surge in "unusual options activity" is signaling a high-stakes... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle? ↗
It's a two-horse race right now, sort of. 
Via The Motley Fool
News headline image
Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom
NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill
Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the... 
Via PredictStreet
Topics Economy Intellectual Property World Trade
News headline image
The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments... 
Via PredictStreet
Topics Economy Government Intellectual Property
News headline image
The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era
Date: December 24, 2025By: Financial Research Insights Introduction As 2025 draws to a close, few companies have dominated the financial and medical headlines as consistently as Eli Lilly and Company... 
Via PredictStreet
Topics Economy
News headline image
Novo Nordisk (NVO) Research: The Oral Wegovy Pivot and the 2026 Outlook
As of December 24, 2025, the pharmaceutical landscape is witnessing a pivotal shift in the treatment of chronic obesity. Novo Nordisk (NYSE: NVO), the Danish titan that pioneered the GLP-1 revolution,... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Hims & Hers Hit A GLP-1 Speed Bump This Year — But Growth Is Just Cooling, Not Cracking ↗
Hims & Hers has drawn scrutiny for selling compounded GLP-1 treatments – lower-cost, unapproved alternatives to blockbuster weight-loss drugs made by Eli Lilly and Novo Nordisk. 
Via Stocktwits
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.